Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.32 |
| ▸ | MME | P08473 | 4/20 | 0.32 |
| ▸ | TP53 | P04637 | 4/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | FASN | P49327 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24380919 | 1.00 | PAK1 (0.34) | PAK1MDM2MMETP53CHRM3 | |
| SCHEMBL16939717 | 0.94 | PAK1 (0.34) | PAK1MDM2MMETP53CHRM3 | |
| SCHEMBL16939713 | 0.94 | PAK1 (0.35) | PAK1MDM2MMETP53CHRM3 | |
| SCHEMBL24380786 | 0.94 | PAK1 (0.35) | PAK1MDM2MMETP53CHRM3 | |
| SCHEMBL16942438 | 0.92 | PAK1 (0.36) | PAK1MDM2MMETP53CHRM3 | |
| SCHEMBL24381008 | 0.92 | PAK1 (0.34) | PAK1MDM2MMETP53CHRM3 | |
| SCHEMBL19086029 | 0.92 | PAK1 (0.34) | PAK1MDM2MMETP53CHRM3 | |
| SCHEMBL16939715 | 0.92 | PAK1 (0.33) | PAK1MDM2MMETP53CHRM3 | |
| SCHEMBL16942444 | 0.90 | PAK1 (0.33) | PAK1 | |
| SCHEMBL16942424 | 0.90 | MME (0.35) | PAK1MMECHRM3ACEFASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193338-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-9839639-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170189399-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-07-06 | — | — | US | disclosed |
| US-9585882-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193338-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | PAK1 2053/4885MDM2 2342/4885MME 1/4885 |
| US-20170189399-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | PAK1 2053/4885MDM2 2342/4885MME 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.